Texas Retina Associates First in U.S. to Dose a Patient in the Phase 2 SIGLEC Trial
On June 1, 2023, Ashkan Abbey, MD, dosed the first patient in the Phase II SIGLEC Trial, a clinical study evaluating AVD-104, a potential new treatment for geographic atrophy (GA) from age-relatedread more
FDA Approves First Treatment for Geographic Atrophy
On February 17, 2023, the U.S. Food and Drug Administration (FDA) approved intravitreal pegcetacoplan (brand name Syfovre), the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Texas Retinaread more
What is Geographic Atrophy?
Approximately 20% of patients with age-related macular degeneration (AMD) will develop a condition called geographic atrophy (GA). It is considered a late stage of AMD and involves chronic, progressive degeneration of regionsread more
Dr. Abbey to Speak at Upcoming Retina World Congress Medical Education Event
On October 24, 2021, Texas Retina Associates’ Ashkan M. Abbey, MD, will serve on a distinguished panel of presenters from across the country for a Retina World Congress continuing medical education (CME)read more